The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
Scalp tattoos can look good but often appear artificial, especially in sunlight or up close, and require regular maintenance. They may boost confidence if done well, but opinions vary on their effectiveness and natural appearance.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
A user who had two hair transplants and is still concerned about their crown area, despite other people reassuring them that it looks normal. The advice given was to use Minoxidil, Finasteride, SMP, and to consider speaking with a therapist.
This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
A user shared their 4-month hair transplant progress with 3740 grafts, showing before and after pictures. They had a generally good experience, except for the anesthesia part.
A 20-year-old is concerned about hairline changes and wonders if it's maturing or male pattern baldness (MPB). Suggestions include consulting a specialist and considering treatments like finasteride or minoxidil.
The user had a hair transplant of 3400 grafts, primarily focusing on the hairline, and is happy with the results four months post-surgery. They used topical minoxidil, oral minoxidil, finasteride, and topical dutasteride, along with microneedling and Nizoral, and the procedure cost around $12,000.
User experienced hair loss after surgery and was diagnosed with TE. The doctor recommended PRP therapy, Finasteride, Anatrix pro Hair Serum, a multivitamin, and a lotion and shampoo containing Zinc Pyrithione.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
A user shared their positive experience with a hair transplant at Moart Clinic, involving approximately 10,000 grafts for a new hairline and crown. The procedure was smooth, with no pain, and the user is very satisfied with the results.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The user started on Finasteride, switched to Dutasteride, and is considering microneedling but was advised against it by their hair surgeon due to potential scalp issues affecting a planned hair transplant. Other users suggest alternatives like Minoxidil, PRP, and avoiding microneedling due to the risk of scar tissue impacting transplant results.
A 23-year-old male had a hair transplant with 3500 grafts and is using finasteride, minoxidil, hair vitamins, and a keto shampoo. He seeks advice on crown regrowth and when to start dermastamping.
Hair transplantation involves a detailed consultation, preparation, and a long-term recovery process with stages like initial shedding and gradual new hair growth over months. Setting realistic expectations is crucial for patient satisfaction.
A user underwent a hair transplant with 3200 grafts and plans to update others on their progress. They previously used minoxidil and finasteride to stabilize hair loss but opted for a transplant for better results.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
The post is about a user's hair transplant results after one week, with 4000 grafts implanted. The conversation includes discussions about the healing process, shedding phase, and the number of grafts used.